Literature DB >> 1316315

Activation of human eosinophils by platelet-derived growth factor.

M K Bach1, J R Brashler, B K Stout, H G Johnson, M E Sanders, A H Lin, R R Gorman, M J Bienkowski, T Ishizaka.   

Abstract

Activated eosinophils are believed to be major contributors to the chronic inflammatory sequelae of asthma, but the details of the mechanism of eosinophil activation in vivo are unknown. In our search for physiologically important modes of eosinophil activation, we studied the effects of recombinant human platelet-derived growth factor (PDGF) on human peripheral blood eosinophils. We compared two activation end-points: secretion of granule contents, exemplified by the release of eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN), and the generation of active oxygen metabolites (O2- production). PDGFc-sis dose dependently stimulated the secretion of large amounts of EPO and EDN from eosinophils. Higher concentrations of PDGF induced a dose-dependent O2- production, especially if the cells were first primed with low concentrations of phorbol ester. These activities were not seen with the AA homodimer of PDGF, suggesting that the activation was receptor dependent. However, several attempts to directly demonstrate the existence of such receptors were unsuccessful. The magnitude of the secretory response to PDGF, and the realization that eosinophils could be easily exposed to this substance as they travel towards the lung, suggests the possibility that this growth factor may be a physiologically important activator of eosinophils in the pulmonary inflammation which is associated with asthma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316315     DOI: 10.1159/000236107

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

Review 1.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

2.  Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension.

Authors:  P P Powell; M Klagsbrun; J A Abraham; R C Jones
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

3.  Angiogenic factors play a significant role in nasal airway remodeling in allergic rhinitis.

Authors:  Hun-Jong Dhong
Journal:  Allergy Asthma Immunol Res       Date:  2011-12-12       Impact factor: 5.764

Review 4.  Eosinophils in glioblastoma biology.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Neuroinflammation       Date:  2012-01-17       Impact factor: 8.322

5.  Role of angiogenic factors in airway remodeling in an allergic rhinitis murine model.

Authors:  Il Joon Moon; Dong-Young Kim; Chae-Seo Rhee; Chul Hee Lee; Yang-Gi Min
Journal:  Allergy Asthma Immunol Res       Date:  2011-11-01       Impact factor: 5.764

6.  Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model.

Authors:  Naomi Suzuki; Nobuhito Sasaki; Yu Utsumi; Hiromi Nagashima; Yutaka Nakamura; Masahiro Yamashita; Kohei Yamauchi; Takashi Sawai
Journal:  Int J Rheum Dis       Date:  2013-05-28       Impact factor: 2.454

7.  A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab.

Authors:  Maho Suzukawa; Nobuharu Ohshima; Hiroyuki Tashimo; Isao Asari; Nobuyuki Kobayashi; Shunsuke Shoji; Shigeto Tohma; Ken Ohta
Journal:  Intern Med       Date:  2020-07-21       Impact factor: 1.271

Review 8.  Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Authors:  Peter Valent; Lina Degenfeld-Schonburg; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Hans-Uwe Simon; Andreas Reiter; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-05-30       Impact factor: 9.623

9.  Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

Authors:  Violaine Havelange; Jean-Baptiste Demoulin
Journal:  J Blood Med       Date:  2013-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.